4.3 Article

Interstitial Lung Disease in Polymyositis and Dermatomyositis

Journal

CLINICS IN CHEST MEDICINE
Volume 40, Issue 3, Pages 561-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccm.2019.05.004

Keywords

Interstitial lung disease; Myositis; Dermatomyositis; Polymyositis

Ask authors/readers for more resources

The idiopathic inflammatory myopathies (Ws), including polymyositis (PM) and dermatomyositis (DM), are autoimmune connective tissue diseases with variable degrees of muscle inflammation and systemic involvement. Interstitial lung disease (ILD) is a common complication of the Ws and is associated with increased mortality. Many patients with PM/DM have myositis-specific and myositis-associated antibodies (MSA/MAAs) that result in distinct clinical phenotypes. Among these MSAs, anti-aminoacyl-tRNA antibodies and anti-melanoma differentiation factor 5 antibodies have high rates of ILD. Corticosteroids are the mainstay of treatment, although the addition of other immunosuppressive therapy is typically necessary to achieve disease control.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available